Rita Samuel

788 total citations
41 papers, 561 citations indexed

About

Rita Samuel is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Rita Samuel has authored 41 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cardiology and Cardiovascular Medicine, 22 papers in Surgery and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Rita Samuel's work include Blood Pressure and Hypertension Studies (26 papers), Lipoproteins and Cardiovascular Health (12 papers) and Hormonal Regulation and Hypertension (11 papers). Rita Samuel is often cited by papers focused on Blood Pressure and Hypertension Studies (26 papers), Lipoproteins and Cardiovascular Health (12 papers) and Hormonal Regulation and Hypertension (11 papers). Rita Samuel collaborates with scholars based in United States, Canada and France. Rita Samuel's co-authors include Dion Zappe, Lawrence A. Leiter, Alexia Letierce, Bertrand Cariou, Dirk Müller‐Wieland, Das Purkayastha, Francisco J. Tinahones, Maja Bujas‐Bobanovic, Stefano Del Prato and Henry R. Black and has published in prestigious journals such as Journal of the American College of Cardiology, Journal of Lipid Research and Drugs.

In The Last Decade

Rita Samuel

40 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rita Samuel United States	14	353	254	220	132	41	41	561
Steven Haffner United States	5	416 1.2×	208 0.8×	504 2.3×	117 0.9×	69 1.7×	5	760
Brian Bryzinski United States	9	262 0.7×	236 0.9×	117 0.5×	97 0.7×	43 1.0×	15	483
Dimokritos S. Demitriadis Greece	7	602 1.7×	276 1.1×	323 1.5×	211 1.6×	101 2.5×	8	810
Lisa Tarasenko United States	11	395 1.1×	184 0.7×	237 1.1×	244 1.8×	31 0.8×	23	645
Valasia V. Athyrou Greece	6	565 1.6×	173 0.7×	314 1.4×	209 1.6×	99 2.4×	6	689
Andrey V. Susekov Russia	6	353 1.0×	182 0.7×	239 1.1×	95 0.7×	61 1.5×	24	564
Jacek Jerzy Jozwiak Poland	12	219 0.6×	198 0.8×	128 0.6×	80 0.6×	56 1.4×	54	503
Rebecca Letterer United States	8	219 0.6×	390 1.5×	166 0.8×	73 0.6×	29 0.7×	8	579
T. LINDÉN Sweden	12	337 1.0×	123 0.5×	171 0.8×	42 0.3×	94 2.3×	16	543

Countries citing papers authored by Rita Samuel

Since Specialization

Citations

This map shows the geographic impact of Rita Samuel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Samuel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Samuel more than expected).

Fields of papers citing papers by Rita Samuel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Samuel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Samuel. The network helps show where Rita Samuel may publish in the future.

Co-authorship network of co-authors of Rita Samuel

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Samuel. A scholar is included among the top collaborators of Rita Samuel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Samuel. Rita Samuel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaudet, Daniel, Maurizio Averna, Maciej Banach, et al.. (2020). EFFICACY AND SAFETY OF ALIROCUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDY. Journal of the American College of Cardiology. 75(11). 1958–1958.

Ray, Kausik K., Stefano Del Prato, Dirk Müller‐Wieland, et al.. (2019). Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology. 18(1). 149–149. 27 indexed citations

Ray, Kausik K., Lawrence A. Leiter, Dirk Müller‐Wieland, et al.. (2018). Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial. Diabetes Obesity and Metabolism. 20(6). 1479–1489. 71 indexed citations

Henry, P., Bertrand Cariou, Maurizio Averna, et al.. (2018). Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants. Archives of Cardiovascular Diseases Supplements. 10(1). 127–127. 1 indexed citations

Leiter, Lawrence A., Francisco J. Tinahones, Dean G. Karalis, et al.. (2018). Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabetic Medicine. 35(12). 1742–1751. 19 indexed citations

Leiter, Lawrence A., Francisco J. Tinahones, Dean G. Karalis, et al.. (2017). ALIROCUMAB SAFETY IN INDIVIDUALS WITH AND WITHOUT DIABETES MELLITUS: POOLED DATA FROM 14 ODYSSEY TRIALS. Journal of the American College of Cardiology. 69(11). 1674–1674. 3 indexed citations

Leiter, Lawrence A., Bertrand Cariou, Dirk Müller‐Wieland, et al.. (2017). Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial. Diabetes Obesity and Metabolism. 19(12). 1781–1792. 100 indexed citations

Cushman, William C., Daniel Duprez, Howard Weintraub, et al.. (2012). Home and clinic blood pressure responses in elderly individuals with systolic hypertension. Journal of the American Society of Hypertension. 6(3). 210–218. 3 indexed citations

Flack, John M., et al.. (2012). Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with Stage 2 hypertension. Journal of the American Society of Hypertension. 6(2). 142–151. 4 indexed citations

10.

Ofili, Elizabeth, Dion Zappe, Das Purkayastha, Rita Samuel, & James R. Sowers. (2012). Antihypertensive and Metabolic Effects of Angiotensin Receptor Blocker/Diuretic Combination Therapy in Obese, Hypertensive African American and White Patients. American Journal of Therapeutics. 20(1). 2–12. 5 indexed citations

11.

Izzo, Joseph L., Howard Weintraub, Daniel Duprez, et al.. (2011). Treating Systolic Hypertension in the Very Elderly With Valsartan-Hydrochlorothiazide vs Either Monotherapy: ValVET Primary Results. Journal of Clinical Hypertension. 13(10). 722–730. 10 indexed citations

12.

Ofili, Elizabeth, Suzanne Oparil, Thomas D. Giles, et al.. (2011). Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. Journal of the American Society of Hypertension. 5(4). 249–258. 6 indexed citations

13.

Wright, Richard F., Daniel Duprez, Das Purkayastha, Rita Samuel, & Keith C. Ferdinand. (2011). Combination Angiotensin‐Receptor Blocker (ARB)/Calcium Channel Blocker With HCTZ vs the Maximal Recommended Dose of an ARB With HCTZ in Patients With Stage 2 Hypertension: The Exforge As Compared to Losartan Treatment in Stage 2 Systolic Hypertension (EXALT) Study. Journal of Clinical Hypertension. 13(8). 588–597. 13 indexed citations

14.

Giles, Thomas D., Suzanne Oparil, Elizabeth Ofili, et al.. (2011). The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Pressure Monitoring. 16(2). 87–95. 14 indexed citations

15.

Sowers, James R., Leopoldo Raij, Brent M. Egan, et al.. (2010). Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. Journal of Hypertension. 28(8). 1761–1769. 27 indexed citations

16.

Oparil, Suzanne, Thomas D. Giles, Elizabeth Ofili, et al.. (2010). Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Journal of Hypertension. 29(1). 161–170. 9 indexed citations

17.

Lacourcière, Yves, Luc Poirier, & Rita Samuel. (2009). Valsartan plus hydrochlorothiazide for first-line therapy in hypertension. Expert Review of Cardiovascular Therapy. 7(12). 1491–1501. 1 indexed citations

18.

Black, Henry R., et al.. (2009). Valsartan. Drugs. 69(17). 2393–2414. 61 indexed citations

19.

Palmer, Biff F., et al.. (2009). Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. Journal of Human Hypertension. 24(7). 483–491. 5 indexed citations

20.

Sherman, David G., et al.. (2005). Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism After Acute Ischemic Stroke: Rationale, Design, and Methods of an Open-Label, Randomized, Parallel-Group Multicenter Trial. Journal of Stroke and Cerebrovascular Diseases. 14(3). 95–100. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact